Trial reportClinical rheumatology2025
High- vs. routine-dose vitamin D3 in severe lupus on pulse methylprednisolone: a randomized, double-blind, placebo-controlled clinical trial.
Trial report in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D dynamics predict treatment response to intravenous glucocorticoids in thyroid-associated ophthalmopathy: a retrospective cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesThis study evaluated high- vs. routine-dose vitamin D3 in severe SLE patients on high-dose glucocorticoids, an underrepresented group in research.
methodsIn a randomized, double-blind, placebo-controlled trial, 40 SLE inpatients receiving intravenous pulse methylprednisolone were assigned to "high-dose" (HD) (100,000 IU of vitamin D3 plus 7000 IU weekly, n = 20) or "routine-dose" (RD) vitamin D3 group (placebo plus 7000 IU weekly, n = 20) for 24 weeks. Changes in disease activity were assessed from baseline to study end.
resultsBaseline SLEDAI scores were comparable between the HD group (median 19) and the RD group (median 14.5; p = 0.230). After 24 weeks, the HD group had a significantly greater increase in 25OHD concentrations (median 15.4 ng/ml) compared to the RD group (median 8.0 ng/ml; p = 0.028). No difference in SLEDAI scores was observed; however, there was a trend toward a greater ΔC4 increase in the HD group (7.38 vs. 3.27, p = 0.093). Δ25OHD showed positive correlations with disease activity markers. ROC analysis identified Δ25OHD cutoffs of 12.9 ng/ml (AUC = 0.741) for C3 and 11.7 ng/ml (AUC = 0.757) for C4 normalization, indicating that exceeding these may improve complement normalization.
conclusionsAlthough SLEDAI scores did not differ between groups, high-dose vitamin D
Indexed as
Identifiers
40818016What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.